
Docket No. 4518-0111PUS1 Appl. No.: NEW Inventor: LOIBNER, Hans et al. 201552324

Title: Immunogenic Recombinant Antibody

NEW SHEET

Sheet 1 of 9

1/9






Figure 2

Docket No. 4518-0111PUS1

WO 2004/091655

Appl. No.: NEW

Inventor: LOIBNER, Hans et al.

Immunogenic Recombinant Antibo Sheet 2 of 9

2/9

KOZAK Xho I

5'...ATA GGC TAG *C CTC GAG CCA CCA CCA T*G CAT CAG ACC AGC ATG GG CATCAAGATGGAATCACAGACTCTGGTCTTCATATCCATACTGCTCTGGTTATATG GAGCTGATGGGAACATTGTAATGACCCAATCTCCCAAATCCATGTCCATGTCAGTA GGAGAGAGGGTCACCTTGACCTGCAAGGCCAGTGAGAATGTGGTTACTTATGTTT CNTGGTATCAACAGAAACCAGAGCAGTCTCCTAAACTGCTGATATATGGGGCATC CAACCGGTACACTGGGGTCCCNGATCGCTTCACAGGCAGTGGATCTGCAACAGA TTTCACTCTGACCATCAGCAGTGTGCAGGCTGAAGACCTTGCAGATTATCACTGT GGACAGGGTTACAGCTATCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATA AAACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGT TAACATCTGGAGGTGCCTCAGTCGTGCTTCTTGAACAACTTCTACCCCAAAGA CATCAATGTCAAGTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCCTGAAC AGTTGGACTGATCAGGACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTCA CGTTGACCAAGGACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCA CAAGACATCAACTTCACCCATTGTCAAGA

> Mlu I Bam HI

GC TTC AAC AGG AAT GAG TGT TAG ACG CGT GGA TCC GCC CCT CTC CCT CCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGT TTGTCTATATGTGATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGG AAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCCTCTCGCCA AAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTC TTGAAGACAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCT GGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAG GCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAAT GGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCC

Appl. No.: NEW

Inventor: LOIBNER, Hans et al.

Immunogenic Recombinant Antibody

Sheet 3 of 9

Docket No. 4518-0111PUS1

3/9

ATTGTATGGGATCTGATCTGGGGCCCCGGACCACGGGGACGT
GAGGTTAAAAAAACGTCTAGGCCCCCGAACCACGGGGACGT

KOZAK Nco I

G GTT TTC CTT TGA AAA ACA CGA TGA TAA TAT GGC CAC CAC CAT GG AATGGAGCAGAGTCTTTATCTTTCTCCTATCAGTAACTGCAGGTGTTCACTCCCAG GTCCAGTTGCAGCAGTCTGGAGCTGAGCTGGTAAGGCCTGGGACTTCAGTGAAG GTGTCCTGCAAGGCTTCTGGATACGCCTTCACTAATTACTTGATAGAGTGGGTAAA GCAGAGGCCTGGACAGGGCCTTGAGTGGATTGGGGTGATTAATCCTGGAAGTGG TCCTCCAGCACTGCCTACATGCAGCTCAGCAGCCTGACATCTGATGACTCTGCGG TCTATTTCTGTGCAAGAGATGGTCCCTGGTTTGCTTACTGGGGCCAAGGGACTCT GGTCACTGTCTCTGCAGCCAAAACAACAGCCCCATCGGTCTATCCACTGGCCCCT GTGTGTGGAGATACAACTGGCTCCTCGGTGACTCTAGGATGCCTGGTCAAGGGTT ATTTCCCTGAGCCAGTGACCTTGACCTGGAACTCTGGATCCCTGTCCAGTGGTGT GCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACCCTCAGCAGCTCAGTG ACTGTAACCTCGAGCACCTGGCCCAGCCAGTCCATCACCTGCAATGTGGCCCAC CCGGCAAGCACCAAGGTGGACAAGAAATTGAGCCCAGAGGGCCCACAATC AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCG TCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATA GTCACATGTGGGGGGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGC TGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGG ATTACAACAGTACTCCCGGGTGGTCAGTGCCCCCCCCCATCCAGCACCAGGACTG GATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAGACCTCCCAGCGCC CATCGAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATAT GTCTTGCCTCCACCAGAAGAAGAGAGATGACTAAGAAACAGGTCACTCTGACCTGCA TGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGGAA AACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACT

Appl. No.: NEW

Inventor: LOIBNER, Hans et al.

Immunogenic Recombinant Antibody

NEW SHEET

Sheet 4 of 9

Docket No. 4518-0111

4/9

TC

Sal I

C CGG ACT CCG GGT AAA TGA GTC GAC

Xba I

GTCTAGGCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATA
AGCTTGCCACAACCCGGGATCCTCTAGA

CCACCATGGTTCGACCATTGAACTGCATCGTCGCCGTGTCCCAAGATATGGGGAT
TGGCAAGAACGGAGACCTACCCTGGCCTCCGCTCAGGAACGAGTTCAAGTACTT
CCAAAGAATGACCACAACCTCTTCAGTGGAAGGTAAACAGAATCTGGTGATTATG
GGTAGGAAAACCTGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGACAGAA
TTAATATAGTTCTCAGTAGAGAACTCAAAGAACCACCACGAGGAGCTCATTTTCTT
GCCAAAAGTTTGGATGATGCCTTAAGACTTATTGAACAACCGGAATTGGCAAGTAA
AGTAGACATGGTTTGGATAGTCGGAGGCAGTTCTGTTTACCAGGAAGCCATGAAT
CAACCAGGCCACCTCAGACTCTTTGTGACAAGGATCATGCAGGAATTTGAAAGTG

Appl. No.: NEW

Inventor: LOIBNER, Hans et al.

e: Immunogenic Recombinant Antibody NEW SHEET

Sheet 5 of 9

Docket No. 4518-0111PUS1

5/9

ACACGTTTTTCCCAGAAATTGATTTGGGGAAATATAAACTTCTCCCAGAATACCCA GGCGTCCTCTGAGGTCCAGGAGGAAAAAGGCATCAAGTATAAGTTTGAAGT Not I

CTACGAGAAGAAGACTAAGCGGCCGC...3' (SEQ ID No1)

Figure 3

Appl. No.: NEW
Inventor: LOIBNER, Hans et al. 10/552324
Title: Immunogenic Recombinant Antibody Sheet 6 of 9

6/9




Figure 4

Appl. No.: NEW
Inventor: LOIBNER, Hans et al.
Title: Immunogenic Recombinant Antibody
NEW SHEET

Sheet 7 of 9

Decket No. 4518-0111PUS1

7/9 ...




Figure 5

Docket No. 4518-0111PUS1

WO 2004/091655

Appl. No.: NEW

Inventor: LOIBNER, Hans et al

Immunogenic Recombi

8/9

Sheet 8 of 9

MEWSRVFIFLLSVTAGVHSQVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVK QRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYF CARDGPWFAYWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPE PVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKV DKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDD PDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNK DLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNN **GKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKS** FSRTPGK (SEQ ID No2)

Figure 6

MHQTSMGIKMESQTLVFISILLWLYGADGNIVMTQSPKSMSMSVGERVTLTCKASENV VTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYH CGQGYSYPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDIN VKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTS TSPIVKSFNRNEC (SEQ ID No3)

Figure 7

MHQTSMGIKMESQTLVFISILLWLYGADGNIVMTQSPKSMSMSVGERVTLTCKASENV VTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYH CGQGYSYPYTFGGGTKLEIRRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDIN VKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTS TSPIVKSFNRNEC (SEQ ID No4)

Appl. No.: NEW

Inventor: LOIBNER, Hans et al.

Immunogenic Recombinant Antibody

NEW SHEET

Sheet 9 of 9

Docket No-4518-0111PUS1

9/9

MHQTSMGIRMESQTLVFISILLWLYGADGNIVMTQSPRSMSMSVGERVTLTCRASEN VVTYVSWYQQRPEQSPRLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLAD YHCGQGYSYPYTFGGGTRLEIRRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKD INVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHICT STSPIVKSFNRNEC (SEQ ID No5)

Figure 9





Figure 10



SEQUENCE LISTING

JC20 Rec'd PST/PTO 07 OCT 2000

```
<110> Igeneon Krebs-Immuntherapie Forschungs- & Entwickl
<120> Immunogenic Recombinant Antibody
<130> Immunogenic Recombinant AB
<140>
<141>
<160> 5
<170> PatentIn Ver. 2.1
<210> 1
<211> 3973
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:mAB 17-1A
<400> 1
ataggetage etegageeae caccatgeat cagaccagea tgggeateaa gatggaatea 60
cagactetgg tetteatate catactgete tggttatatg gagetgatgg gaacattgta 120
atgacccaat ctcccaaatc catgtccatg tcagtaggag agagggtcac cttgacctgc 180
aaggccagtg agaatgtggt tacttatgtt tentggtate aacagaaace agagcagtet 240
ectaaactge tgatatatgg ggcatecaae eggtacaetg gggteeenga tegetteaca 300
ggcagtggat ctgcaacaga tttcactctg accatcagca gtgtgcaggc tgaagacctt 360
gcagattatc actgtggaca gggttacagc tatccgtaca cgttcggagg ggggaccaag 420
ctggaaataa aacgggctga tgctgcacca actgtatcca tcttcccacc atccagtgag 480
cagttaacat ctggaggtgc ctcagtcgtg tgcttcttga acaacttcta ccccaaagac 540
atcaatgtca agtggaagat tgatggcagt gaacgacaaa atggcgtcct gaacagttgg 600
actgatcagg acagcaaaga cagcacctac agcatgagca gcaccctcac gttgaccaag 660
gacgagtatg aacgacataa cagctatacc tgtgaggcca ctcacaagac atcaacttca 720
cccattgtca agagettcaa caggaatgag tgttagacge gtggateege eceteteeet 780
eccececce taacgttact ggeegaagee gettggaata aggeeggtgt gegtttgtet 840
atatgtgatt ttccaccata ttgccgtctt ttggcaatgt gagggcccgg aaacctggcc 900
ctgtcttctt gacgagcatt cctaggggtc tttcccctct cgccaaagga atgcaaggtc 960
tgttgaatgt cgtgaaggaa gcagttcctc tggaagcttc ttgaagacaa acaacgtctg 1020
tagegaeeet ttgeaggeag eggaaeeeee caeetggega eaggtgeete tgeggeeaaa 1080
agccacgtgt ataagataca cctgcaaagg cggcacaacc ccagtgccac gttgtgagtt 1140
ggatagttgt ggaaagagtc aaatggctct cctcaagcgt attcaacaag gggctgaagg 1200
atgcccagaa ggtaccccat tgtatgggat ctgatctggg gcctcggtgc acatgcttta 1260
catgtgttta gtcgaggtta aaaaaacgtc taggcccccc gaaccacggg gacgtggttt 1320
teetttgaaa aacaegatga taatatggee accaecatgg aatggageag agtetttate 1380
tttctcctat cagtaactgc aggtgttcac tcccaggtcc agttgcagca gtctggagct 1440
```

```
gagctggtaa ggcctgggac ttcagtgaag gtgtcctgca aggcttctgg atacgccttc 1500
actaattact tgatagagtg ggtaaagcag aggcctggac agggccttga gtggattggg 1560
gtgattaatc ctggaagtgg tggtactaac tacaatgaga agttcaaggg caaggcaaca 1620
ctgactgcag acaaatcctc cagcactgcc tacatgcagc tcagcagcct gacatctgat 1680
gactetgegg tetatttetg tgcaagagat ggteeetggt ttgettaetg gggeeaaggg 1740
actotggtca ctgtctctgc agccaaaaca acagccccat cggtctatcc actggcccct 1800
gtgtgtggag atacaactgg ctcctcggtg actctaggat gcctggtcaa gggttatttc 1860
cctgagccag tgaccttgac ctggaactct ggatccctgt ccagtggtgt gcacaccttc 1920
ccagctgtcc tgcagtctga cctctacacc ctcagcagct cagtgactgt aacctcgagc 1980
acctggccca gccagtccat cacctgcaat gtggcccacc cggcaagcag caccaaggtg 2040
gacaagaaaa ttgagcccag agggcccaca atcaagccct gtcctccatg caaatgccca 2100
gcacctaacc tettgggtgg accateegte tteatettee etecaaagat caaggatgta 2160
ctcatgatct ccctgagccc catagtcaca tgtgtggtgg tggatgtgag cgaggatgac 2220
ccagatgtcc agatcagctg gtttgtgaac aacgtggaag tacacacagc tcagacacaa 2280
acceatagag aggattacaa cagtactete egggtggtea gtgeceteee cateeageae 2340
caggactgga tgagtggcaa ggagttcaaa tgcaaggtca acaacaaaga cctcccagcg 2400
cccatcgaga gaaccatctc aaaacccaaa gggtcagtaa gagctccaca ggtatatgtc 2460
ttgcctccac cagaagaaga gatgactaag aaacaggtca ctctgacctg catggtcaca 2520
qacttcatgc ctgaagacat ttacgtggag tggaccaaca acgggaaaac agagctaaac 2580
tacaagaaca ctgaaccagt cctggactct gatggttctt acttcatgta cagcaagctg 2640
agagtggaaa agaagaactg ggtggaaaga aatagctact cctgttcagt ggtccacgag 2700
ggtctgcaca atcaccacac gactaagagc ttctcccgga ctccgggtaa atgagtcgac 2760
acgcgtcgag catgcatcta gggcggccaa ttccgcccct ctccctcccc ccccctaac 2820
gttactggcc gaagccgctt ggaataaggc cggtgtgcgt ttgtctatat gtgattttcc 2880
accatattgc cgtcttttgg caatgtgagg gcccggaaac ctggccctgt cttcttgacg 2940
agcattecta ggggtettte ecetetegee aaaggaatge aaggtetgtt gaatgtegtg 3000
aaggaagcag ttcctctgga agcttcttga agacaaacaa cgtctgtagc gaccctttgc 3060
aggcagcgga accccccacc tggcgacagg tgcctctgcg gccaaaagcc acgtgtataa 3120
gatacacctg caaaggegge acaaccecag tgecaegttg tgagttggat agttgtggaa 3180
agagtcaaat ggctctcctc aagcgtattc aacaaggggc tgaaggatgc ccagaaggta 3240
ccccattgta tgggatctga tctggggcct cggtgcacat gctttacatg tgtttagtcg 3300
aggttaaaaa aacgtctagg ccccccgaac cacggggacg tggttttcct ttgaaaaaca 3360
cgatgataag cttgccacaa cccgggatcc tctagaccac catggttcga ccattgaact 3420.
gcategtege egtgteceaa gatatgggga ttggcaagaa eggagaeeta eeetggeete 3480
cgctcaggaa cgagttcaag tacttccaaa gaatgaccac aacctcttca gtggaaggta 3540
aacagaatct ggtgattatg ggtaggaaaa cctggttctc cattcctgag aagaatcgac 3600
ctttaaagga cagaattaat atagttctca gtagagaact caaagaacca ccacgaggag 3660
ctcattttct tgccaaaagt ttggatgatg ccttaagact tattgaacaa ccggaattgg 3720
caagtaaagt agacatggtt tggatagtcg gaggcagttc tgtttaccag gaagccatga 3780
atcaaccagg ccacctcaga ctctttgtga caaggatcat gcaggaattt gaaagtgaca 3840
cgtttttccc agaaattgat ttggggaaat ataaacttct cccagaatac ccaggcgtcc 3900
tctctgaggt ccaggaggaa aaaggcatca agtataagtt tgaagtctac gagaagaaag 3960
actaagcggc cgc
                                                                  3973
```

<210> 2 <211> 465

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 2

Met Glu Trp Ser Arg Val Phe Ile Phe Leu Leu Ser Val Thr Ala Gly
1 5 10 15

Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg
20 25 30

Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe 35 40 45

Thr Asn Tyr Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60

Glu Trp Ile Gly Val Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asn 65 70 75 80

Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Ser 90 95

Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val 100 105 110

Tyr Phe Cys Ala Arg Asp Gly Pro Trp Phe Ala Tyr Trp Gly Gln Gly
115 120 125

Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Ala Pro Ser Val Tyr . 130 135 140

Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu 145 150 155 160

Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp 165 170 175

Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu 180 185 190

Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser 195 200 205

Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser 210 215 220

Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys

225					230	·				235					240
Pro	Cys	Pro	Pro	Cys 245	Lys	Cys	Pro	Ala	Pro 250	Asn	Leu	Leu	Gly	Gly 255	Pro
Ser	Val	Phe	11e 260	Phe	Pro	Pro	Lys	Ile 265	Lys	Asp	Val	Leu	Met 270	Ile	Ser
Leu	Ser	Pro 275	Ile	Val	Thr	Cys	Val 280	Val	Val	Asp	Val	Ser 285	Glu	Asp	Asp
Pro	Asp 290	Val	Gln	Ile	Ser	Trp 295	Phe	Val	Asn	Asn	Val 300	Glu	Val	His	Thr
Ala 305	Gln	Thr	Gln	Thr	His 310	Arg	Glu	Asp	Tyr	Asn 315	Ser	Thr	Leu	Arg	Val 320
Val	Ser	Ala	Leu	Pro 325	Ile	Gln	His	Gln	Asp 330	Trp	Met	Ser	Gly	Lys 335	Glu
Phe	Lys	Cys	Lys 340	Val	Asn	Asn	Lys	Asp 345	Leu	Pro	Ala	Pro	11e 350	Glu	Arg
Thr	Ile	Ser 355	Lys	Pro	Lys	Gly	Ser 360	Val	Arg	Ala	Pro	Gln 365	Val	Tyr	Val
Leu	Pro 370	Pro	Pro	Glu	Glu	Glu 375	Met	Thr	Lys	Lys	Gln 380	Val	Thr	Leu	Thr
Cys 385	Met	Val	Thr	Asp	Phe 390	Met	Pro	Glu	Asp	Ile 395	Tyr	Val	Glu	Trp	Thr 400
Asn	Asn	Gly	Lys	Thr 405	Glu	Leu	Asn	Tyr	Lys 410	Asn	Thr	Glu	Pro	Val 415	Leu
Asp	Ser	Asp	Gly 420	Ser	Tyr	Phe	Met	Tyr 425	Ser	Lys	Leu	Arg	Val 430	Glu	Lys
Lys	Asn	Trp 435	Val	Glu	Arg	Asn	Ser 440	Tyr	Ser	Cys	Ser	Val 445	Val	His	Glu
Gly	Leu 450	His	Asn	His	His	Thr 455	Thr	Lys	Ser	Phe	Ser 460	Arg	Thr	Pro	Gly
Lys 465															

<210> 3

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 3

Met His Gln Thr Ser Met Gly Ile Lys Met Glu Ser Gln Thr Leu Val 1 5 10 15

Phe Ile Ser Ile Leu Leu Trp Leu Tyr Gly Ala Asp Gly Asn Ile Val 20 25 30

Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly Glu Arg Val 35 40 45

Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr Val Ser Trp
50 55 60

Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile Tyr Gly Ala 65 70 75 80

Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 85 90 95

Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu 100 105 110

Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr Phe Gly 115 120 125

Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val

Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser 145 150 155 160

Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys
165 170 175

Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp
180 185 190

Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu 195 200 205

Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu 210 215 220

Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg 225 230 235 240

Asn Glu Cys

<210> 4

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 4

Met His Gln Thr Ser Met Gly Ile Lys Met Glu Ser Gln Thr Leu Val 1 5 10 15

Phe Ile Ser Ile Leu Leu Trp Leu Tyr Gly Ala Asp Gly Asn Ile Val 20 25 . 30

Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly Glu Arg Val 35 40 45

Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr Val Ser Trp
50 55 60

Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile Tyr Gly Ala 65 70 75 80

Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 85 90 95

Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu 100 105 110

Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr Phe Gly
115 120 125

Gly Gly Thr Lys Leu Glu Ile Arg Arg Ala Asp Ala Ala Pro Thr Val 130 135 140

Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser 145 150 155 160

Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys
165 170 175

Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp
180 185 190

Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu
195 200 205

Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu 210 215 220

Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg 225 230 235 240

Asn Glu Cys

<210> 5

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 5

Met His Gln Thr Ser Met Gly Ile Arg Met Glu Ser Gln Thr Leu Val 1 5 10 15

Phe Ile Ser Ile Leu Leu Trp Leu Tyr Gly Ala Asp Gly Asn Ile Val 20 25 30

Met Thr Gln Ser Pro Arg Ser Met Ser Met Ser Val Gly Glu Arg Val 35 40 45

Thr Leu Thr Cys Arg. Ala Ser Glu Asn Val Val Thr Tyr Val Ser Trp
50 55 60

Tyr Gln Gln Arg Pro Glu Gln Ser Pro Arg Leu Leu Ile Tyr Gly Ala 65 70 75 80

Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 85 90 95

Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu

Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Arg Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys